

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 061 333
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82301460.0

(22) Date of filing: 22.03.82

(51) Int. Cl.³: **C 07 D 498/10**
A 61 K 31/535
/(C07D498/10, 265/00, 221/00)

(30) Priority: 23.03.81 US 246459

(43) Date of publication of application:
29.09.82 Bulletin 82/39(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE


(71) Applicant: **SYNTEX (U.S.A.) INC.**
3401 Hillview Avenue
Palo Alto, California 94304(US)

(72) Inventor: **Clark, Robin D.**
2295 Columbia Street
Palo Alto California 94306(US)

(74) Representative: **Armitage, Ian Michael et al,**
MEWBURN ELLIS & CO. 2/3 Cursitor Street
London EC4A 1BQ(GB)

(54) 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones.

(57) Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula



wherein:

R, R¹, R², R³, and R⁴ are independently hydrogen or lower alkyl of one to four carbon atoms; and

R⁵ and R⁶ are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; and

the pharmaceutically acceptable acid addition salts thereof.

EP 0 061 333 A1

THIS PAGE BLANK (USPTO)

5

-1-

10

9-[2-(3-INDOLYL)ETHYL]-1-OXA-4,9-
DIAZASPIRO[5.5]UNDECAN-3-ONES

15

This invention relates to 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones and the pharmaceutically acceptable acid addition salts thereof, which can be useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, edema, migraine, vasospastic disorders, and asthma. The invention also relates to a pharmaceutically acceptable composition containing an effective amount of at least one of the compounds in combination with a suitable excipient. Such a composition can be useful for the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma in mammals. The invention also relates to a process for making the compounds of the invention.


30

It is known that compounds of the formula

35

THIS PAGE BLANK (USPTO)


-2-



wherein R^1 , R^2 , R^3 and R^4 are, i.a., independently
 10 hydrogen or alkyl of one to six carbon atoms and R^5 and
 R^6 are, i.a., independently hydrogen, alkyl of one to six
 carbon atoms, or alkoxy of one to six carbon atoms
 exhibit antihypertensive, diuretic, antihistamine,
 antiallergic and bronchodilating activity as well as are
 15 useful in the treatment of migraine and vasospastic
 disorders. See U.S. 4,255,432 and Chimie Therapeutique,
 Nove.- Dec. 1972, No. 6, pp. 458-466. A novel class of
 compounds has now been prepared which are more active
 than the compounds of the related disclosures.

20

The first aspect of this invention is the group of
 compounds represented by the formula



30

wherein:

R , R^1 , R^2 , R^3 , and R^4 are independently hydrogen or
 lower alkyl of one to four carbon atoms; and

35 R^5 and R^6 are independently hydrogen, lower alkyl of
 one to four carbon atoms or lower alkoxy of one to four.

THIS PAGE BLANK (USPTO)

-3-


carbon atoms; and

the pharmaceutically acceptable acid addition salts thereof.

Another aspect of the invention is a composition
5 useful in the prevention and/or treatment of
hypertension, congestive heart failure, arrhythmia,
migraine, vasospastic disorders and asthma in mammals
which composition comprises an effective amount of at
least one compound chosen from those represented by
10 formula (I) above or a pharmaceutically acceptable acid
addition salt thereof and a pharmaceutically suitable
excipient.

Still another aspect of the invention is, for use
in preventing and/or treating hypertension, congestive
15 heart failure, arrhythmia, migraine, vasospastic
disorders and asthma in mammals, at least one compound
chosen from those represented by formula (I) above.

20 Still another aspect of the invention is a process
for preparing a compound of formula (I) above which
comprises reacting a compound of the formula




30 wherein:

R, R¹, and R² are as defined above with a suitable
indolyethyl halide of the formula

35

THIS PAGE BLANK (USPTO)



5

wherein:

R³, R⁴, R⁵, and R⁶ are as defined above and X is a halide, e.g., chloro or bromo.

A preferred group of compounds of formula (I) is
10 that wherein R is lower alkyl and R¹, R², R³, R⁴, R⁵ and R⁶ are hydrogen, the most preferred group being wherein R is methyl or ethyl and the pharmaceutically acceptable acid addition salts thereof.

Another preferred group of compounds of formula (I)
15 is that in which all R's are each hydrogen, namely,

THIS PAGE BLANK (USPTO)

9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one and the pharmaceutically acceptable acid addition salts thereof.

As used in the specification and the appended
5 claims, unless specified to the contrary, the following terms have the meaning indicated. The term "lower alkyl" refers to a straight or branched chain monovalent substituent consisting solely of carbon and hydrogen, containing no unsaturation and having from one to four
10 carbon atoms. Examples of lower alkyl groups are methyl, ethyl, i-propyl and t-butyl. The term "lower alkoxy" refers to a monovalent substituent containing oxygen and of the formula "lower alkyl-O-" wherein lower alkyl is as defined above. Examples of lower alkoxy groups are
15 methoxy, ethoxy, n-propoxy and i-butoxy. The term "pharmaceutically acceptable acid addition salts" refers to salts of the subject compounds which possess the desired pharmacological activity and which are neither biologically nor otherwise undesirable. These salts are
20 formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid; or organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, malic acid, maleic acid,
25 fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and the like.

The compounds of the present invention are named according to the IUPAC nomenclature system. The locants
30 for the substituents on the ring systems of the compounds of the instant invention are as depicted above.

Certain compounds of formula (I) wherein R and R¹ are lower alkyl may have geometric(cis and trans) isomers. The geometric isomers may be separated by
35 various methods, for example, selective crystallization

THIS PAGE BLANK (USPTO)

and column chromatography. Alternatively, where, appropriate, the intermediates of formula (VIII) (infra) may be separated and converted to the final cis or trans isomers of compounds of formula (I). Both geometric
5 isomers as well as mixtures thereof are intended to be included within the scope of the present invention.

Compounds of formula (I) also exist as optical isomers because the spiral ring group does not possess a plane of symmetry. Accordingly, the compounds of the
10 present invention may be prepared in either optically active form, or as a racemic mixture. Unless otherwise specified, the compounds described herein are all in the racemic form. However, the scope of the subject invention herein is not to be considered limited to the
15 racemic form but to encompass the individual optical isomers of the subject compounds.

If desired, racemic intermediates of formula (VIII) (infra) or final products prepared herein may be resolved into their optical antipodes by conventional resolution
20 means known per se, for example, by the separation (e.g., fractional crystallization) of the diastereomeric salts formed by reaction of, e.g., racemic compounds of formula (I) or the intermediate of formula (VIII) (infra) with an optically active acid. Exemplary of such optically
25 active acids are the optically active forms of camphor-10-sulfonic acid, α -bromocamphor- η -sulfonic acid, camphoric acid, menthoxyacetic acid, tartaric acid, malic acid, diacetyltartaric acid, pyrrolidone-5-carboxylic acids, and the like. The separated pure diastereomeric
30 salts may then be cleaved by standard means to afford the respective optical isomers of the compounds of formula (I) or the intermediate of formula (VIII) (infra).

ADMINISTRATION AND FORMULATION

Another aspect of the present invention relates to
35 pharmaceutical compositions useful in the prevention

THIS PAGE BLANK (1/10/2021)

and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma, particularly in the prevention and/or treatment of hypertension in a mammalian subject comprising a compound of formula (I), or a pharmaceutically acceptable acid addition salt thereof, in admixture with a pharmaceutically acceptable non-toxic carrier. Useful pharmaceutical carriers for the preparation of the pharmaceutical compositions hereof can be solids or liquids. Thus, the compositions can take the form of tablets, pills, capsules, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like. Carriers can be selected from the various oils, including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers particularly for injectable solutions. Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. Suitable pharmaceutical carriers and their formulations are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will, in any event, contain a therapeutically effective amount of the active compound together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the subject. Thus, the level of the drug in the formulation can vary from 5 percent weight (%W) to 95%W of the drug based on the total formulation and about 5%W to 95%W excipient. Preferably the drug is present at a level of 10%W to 70%W.

Another aspect of the present invention relates to a

THIS PAGE BLANK (1577)

method for preventing and/or treating hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders and asthma in a mammalian subject comprising administering a therapeutically effective
5 amount of a compound of formula (I), or a pharmaceutically acceptable acid addition salt thereof.

In the practice of the above described methods of the present invention a therapeutically effective amount of the compound of formula (I) or a pharmaceutical
10 composition containing same is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound or compounds of the present invention or other pharmaceutical agents. These compounds or compositions
15 can thus be administered orally, systemically (i.e., intranasally, or by suppository) or parenterally (i.e., intramuscularly, subcutaneously and intravenously), and can be administered either in the form of solid or liquid dosages including tablets, solutions, suspensions,
20 aerosols, and the like, as discussed in more detail hereinabove.

The formulation can be administered in a single unit dosage form for continuous treatment or prevention or in a single unit dosage form ad libitum when relief of
25 symptoms is specifically required.

In view of the foregoing as well as in consideration of the degree of severity of the condition being treated, age of subject and so forth, all of which factors are determinable by routine experimentation by one skilled in
30 the art, the effective dosage in accordance herewith can vary over a wide range. Generally, a therapeutically effective amount ranges from about 0.01 to about 5 mg./kg. body weight per day and preferably, for example, for antihypertensive use, from about 1 to about
35 3 mg./kg. body weight per day. In alternative terms, for

THIS PAGE BLANK (USPTO)

an average adult human subject, a therapeutically effective amount in accordance herewith would be, in preferred embodiments from about 7 mg. to about 120 mg. per day per subject.

5

PROCESS OF THE INVENTION


Compounds of formula (I) are prepared by the reaction sequence shown below.

Reaction Sequence

10


15

20



25


30



35

THIS PAGE BLANK (USPTO)

-10-



wherein R, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above and X is chloro or iodo.

20 In the above sequence, 4-piperidone(A), available from Aldrich Chemical Co., is reacted with benzyl chloroformate, also available from Aldrich Chemical Co., by the method described in Organic Chemistry, by Robert T. Morrison and Robert N. Boyd, 2nd Edition, Ch. 37, p. 1112 to yield the N-protected-4-piperidone of formula (II). Typically, the reaction is carried out in a solvent such as water and is cooled to a temperature of about 0°C to about 25°C, preferably from about 5°C to about 15°C for 3 hours to 24 hours, preferably 6 hours to 12 hours. The 4-piperidone is in a molar ratio of 0.7 to 0.8 mole to 1 mole of benzyl chloroformate, particularly in a molar ratio of 0.75 mole of 4-piperidone to 1 mole of benzyl chloroformate.

25 30

The N-protected piperidine epoxide of formula (IV) 35 wherein R is hydrogen is prepared by the method described

THIS PAGE BLANK (USPTO)

in J. Am. Chem. Soc., 81, 1353 (1965). N-protected piperidone, dispersed or dissolved in a suitable liquid such as dimethyl sulfoxide, tetrahydrofuran and the like is reacted with an ylid formed by the reaction of
5 trimethyl sulfonium or trimethyl sulfoxonium iodide with an alkali metal hydride such as sodium hydride. Typically, the reactants, in a molar ratio of from 1 to 2 moles, preferably from 1.3 to 1.6 moles of ylid to 1 mole of N-protected-4-piperidone, are stirred at a temperature
10 of between 0°C to 30°C, preferably at room temperature for about 10 hours to 24 hours, preferably for about 12 hours to 18 hours. This is followed by heating at 40°C to about 100°C, preferably from about 50°C to 60°C, for 15 minutes to about 2 hours, preferably for about 45
15 minutes to about 1.5 hours.

The epoxides of formula (IV) wherein R is lower alkyl are prepared by first preparing the olefin of formula (III) then epoxidizing the olefin by methods well known in the art such as by the catalytic oxidation of
20 the C-C double bond with air or by peroxidation of the C-C double bond with a peroxy acid such as peroxybenzoic acid. The compounds of formula (III) are prepared by the well known Wittig reaction in which N-protected piperidone is reacted with a
25 methylenetriphenylphosphorane ylid of the formula $\text{Ph}_3\text{P}=\text{CHR}$ wherein R is as defined above. The ylid is prepared by reacting triphenylphosphine with an RCH_2 halide wherein R is as defined above followed by reaction with an organolithium compound such as phenyllithium or
30 n-butyllithium. The reaction conditions for the preparation of the ylid and the olefin are thoroughly discussed in "The Wittig Reaction" by Adalbert Maercker in Organic Reaction V. 14, Ch. 3, p. 270 (1965).

The epoxide ring of compounds of formula (IV) is
35 readily opened at elevated temperatures by any

THIS PAGE BLANK (USPTO)

R¹-substituted amine wherein R¹ is as defined above forming 1-carbobenzoxy-4-hydroxy-4-(R¹-aminomethyl)-piperidine of formula (V). Typically, the reactants are heated at a temperature of between about 75°C to about 175°C, preferably from about 100°C to about 125°C for about 3 hours to about 24 hours, preferably for about 3 hours to about 6 hours. The reaction is typically conducted in a solution of the R¹-substituted amine in an alcohol such as ammonia in methanol at a molar ratio of N-protected piperidine epoxide to amine of 1 mole to 50 moles, preferably of 1 mole to 20 moles.

The hydroxy amine compounds of formula (V) are reacted with an α -chloroacid chlorides such as α -chloroacetyl chloride, α -chloropropionylchloride, α -chloro-n-butyryl chloride and the like in a polar aprotic solvent such as ethyl acetate, tetrahydrofuran, dimethyl formamide and the like optionally followed by reaction with an alkali metal iodide such as sodium iodide to yield compounds of formula (VI) wherein X is chloro or iodo. The reaction is run in the presence of a suitable acid acceptor such as trimethylamine, triethylamine, an alkali metal carbonate such as sodium or potassium carbonate and the like at a temperature from about 0°C to about 25°C, preferably from about 5°C to about 10°C.

The α -chloroacid chlorides which are not readily available may be prepared by conventional methods such as the Hell-Volhard-Zelinsky Reaction in which the appropriate acid is reacted with chlorine in the presence of phosphorus. See, for example, Organic Chemistry by Robert T. Morrison and Robert N. Boyd, 2nd Edition, Ch. 18, p. 604 and Chem. Revs. 7, 180 (1930).

Cyclization of compounds of formula (VI) is carried out by contacting compounds of formula (VI) with a strong base such as an alkali metal alkoxide dissolved in an

THIS PAGE BLANK (USPTO)

alcohol (e.g. potassium t-butoxide in t-butyl alcohol) in a polar aprotic solvent such as tetrahydrofuran, dimethylformamide and the like. The mixture is refluxed for about 0.1 hour to about 1 hour, preferably for about 0.1 hour to about 0.2 hour.

5 The compounds of formula (VII) are treated with hydrogen bromide in acetic acid to remove the N-protecting group to yield compounds of formula (VIII).

10 The intermediate 3-(2-haloethyl)indoles are readily prepared by reacting a solution or dispersion of the unsubstituted or substituted-3-(2-hydroxyethyl)indole with a phosphorus trihalide, a triphenyl phosphine halogen adduct or a triphenoxyphosphorus alkyl halide. The reaction is typically carried out in an inert
15 reaction medium such as dimethylformamide, diethylether and the like from about room temperature to about 100°C using an excess of a halogenating agent, e.g., 1.1 to 3.0 times the molar equivalence of the hydroxyethylindole. The haloethylindole intermediate is preferably isolated
20 before being used in the reaction with compounds of formula (VIII), the isolation being accomplished by conventional means.

The hydroxyethylindoles which are not readily available may be prepared by methods well known in the
25 art. For example, when R³ is lower alkyl and R⁵ and/or R⁶ are hydrogen, lower alkoxy, or lower alkyl, the substituted hydroxyethylindoles may be prepared by the methods described in U.S. 3,294,804 in which aniline or a substituted aniline is reacted with a halogenated
30 ketoacid alkyl ester at a temperature of about 170°C to about 190°C for five to twenty minutes. The resultant indole acetic acid is reduced to the alcohol with lithium aluminium hydride.

The hydroxyethylindoles wherein R⁵ and/or R⁶ are
35 lower alkyl and R³ is hydrogen are obtained by the method

THIS PAGE BLANK (USPTO)

described in J. Amer. Chem. Soc., 76, 2206 (1953) and U.S. 3,316,160 followed by reduction to the alcohol. The substituted phenylhydrazine is reacted with β -formylpropionic acid ester and then cyclized to the indole acetic acid. The indole acetic acid is reduced to the hydroxyethylindole by conventional means well known in the art such as with lithium aluminum hydride.

The phenylhydrazines which are not readily available may be prepared by diazotizing the appropriately substituted aniline with sodium nitrite and hydrochloric acid, then treating with sodium sulfite followed by treatment with sodium hydroxide as described in Organic Synthesis, 2nd Ed., coll. vol. 1, 442 (1941).

The hydroxyethylindoles wherein R^4 is lower alkyl may be prepared by alkylation with the appropriate alkyl halide, for example, methyl iodide, ethyl iodide and the like.

The compounds of the instant invention are prepared by treating the 3-(2-haloethyl)indole intermediate with the compound of formula (VIII) in the presence of the acid acceptor in an inert organic solvent such as dimethylformamide, tetrahydrofuran and the like at a temperature from about -10°C to 120°C , preferably from about 50°C to about 100°C for about 6 hours to about 48 hours, preferably from about 16 hours to about 18 hours. Effective acid acceptors are organic bases such as trialkyl amines, e.g., trimethylamine, triethylamine and quinuclidine and inorganic bases such as alkali metal carbonates, for example, sodium carbonate or potassium carbonate and alkali metal hydroxide such as sodium hydroxide, potassium hydroxide and the like.

The compounds of formula (I) may be isolated as free bases, but it is more convenient to isolate the compounds of the instant invention as acid addition salts. These salts are prepared in the usual manner, i.e., by reaction

THIS PAGE BLANK (USPTO)

of the free base with a suitable organic or inorganic acid, for example, one of the pharmaceutically acceptable acids described above. If desired, the salt can be readily converted to the free base by treatment with a base such as potassium or sodium carbonate or potassium or sodium hydroxide.

The following specific description is given to enable those skilled in the art to more clearly understand and practice the invention. It should not be considered as a limitation upon the scope of the invention but merely as being illustrative and representative thereof.

PREPARATION 1

(Preparation of compounds of formula (IV) wherein R is hydrogen)

In a 250 ml flask under argon was mixed 1.2 g mineral oil-free sodium hydride, 11 g trimethylsulfoxonium iodide and 60 ml dimethylsulfoxide. The mixture was stirred for two hours and then was added 9.32 g of N-carbobenzyloxy-4-piperidone, the stirring being continued at room temperature for 30 minutes, followed by 50° for one hour, then room temperature for 18 hours. The mixture was poured into 300 ml water and extracted with three 70 ml portions of diethyl ether. The combined diethyl ether extracts were washed with 50 ml water. Removal of solvent by evaporation afforded 3.8 g of crude 1-carbobenzoxypiperidin-4-epoxide.

THIS PAGE BLANK (USPTO)

PREPARATION 2

(Preparation of compounds of formula (IV) wherein R is lower alkyl)

5 A) Butyl lithium (44 ml of 1.6M in hexane) was added slowly to a stirred suspension of 27 g of (n-propyl)-triphenylphosphonium bromide in 350 ml of tetrahydrofuran and the resulting solution was refluxed for 1 hour. The mixture was cooled in an ice bath and
10 18 g of N-carbobenzyloxy-4-piperidone was added. After stirring at room temperature of 0.5 hour, the solution was refluxed for 2 hours. The cooled mixture was concentrated under reduced pressure, partitioned between ether and water, and the ether was dried (sodium sulfate)
15 and evaporated. The residue was filtered through silica gel with 20% ethyl acetate-hexane to give 10 g of 1-carbobenzoxo-4,1'-epoxybutylpiperidine as a colorless oil.

 B) The above olefin (13.3 g) in 150 ml of
20 chloroform at 50°C was treated with 12 g of m-chloroperoxybenzoic acid and the resulting solution was kept at 5°C for 20 hours. The chloroform was washed with 5% sodium hydroxide solution and evaporated to afford 14 grams of 1-carbobenzoxo-4,1'-epoxybutyl-
25 piperidine as a colorless oil.

 C) Similarly, proceeding as in Part A and B above, substituting the appropriate R-triphenylphosphonium bromide for (n-propyl)triphenylphosphonium bromide the following compounds are prepared:

30 1-carbobenzoxo-4,1'-epoxyethylpiperidine, R is methyl;

 1-carbobenzoxo-4,1'-epoxypropylpiperidine, R is ethyl;

 1-carbobenzoxo-4,1'-epoxy-2-methylpropyl-
35 piperidine, R is i-propyl; and

THIS PAGE BLANK (USPTO)

1-carbobenzoxo-4,1'-epoxypentylpiperidine, R is n-butyl.

PREPARATION 3

5

(Preparation of compounds of formula (VI))

A) A solution of 77 g of 1-carbobenzoxypiperidin-4-epoxide in 1 liter of 15% ammonia-methanol was heated in a steel bomb at 100° for 24 hours. The mixture was cooled and evaporated and the residue was dissolved in 600 ml of ethyl acetate. Water (500 ml) and 125 g of potassium carbonate were added and the two phase mixture was cooled to 5°C and 35 ml of chloroacetyl chloride was slowly added. The ethyl acetate layer was separated and evaporated to a residue which was dissolved in 400 ml of acetone. Sodium iodide (75 g) was added and the solution was stirred for 12 hours at reflux. The solvent was evaporated and the residue was partitioned between water and ethyl acetate. The ethyl acetate was evaporated and the residue was filtered through 1.25 kg of silica gel with ethyl acetate eluent to afford 59.6 g of 1-carbobenzoxo-4-hydroxy-4-(1-iodoacetylamidomethyl)piperidine as a white solid; mp 115-117°C.

B) A solution of potassium t-butoxide (25g) in t-butanol (600 ml) was refluxed while a solution of 1-carbobenzoxo-4-hydroxy-4-(1-iodoacetylamidomethyl)piperidine (50g) in tetrahydrofuran (300 ml) was slowly added. The mixture was neutralized with acetic acid, evaporated, dissolved in ethyl acetate and washed with water. Evaporation of the ethyl acetate left a residue which was triturated with ether to afford 90 g of solid. This material (70g) was dissolved in 400 ml of 2N HBr in acetic acid and stirred for 1 hour. The precipitate was filtered and washed with ether to give 70g of the

35

THIS PAGE BLANK (USPTO)

hydrobromide salt of 1-oxa-4,9-diazaspiro[5.5]undecan-3-one as a white solid; mp 200-202°C.

C) Similarly, proceeding as in Parts A and B above, but substituting methylamine, ethylamine, n-propylamine, and i-butylamine for ammonia, the following compounds are prepared:

4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
4-n-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

10 and

4-i-butyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

D) Similarly, proceeding as in Parts A and B above, but substituting the appropriate epoxide from Preparation 2 for 1-carbobenzoxypiperidin-4-epoxide, the following compounds are prepared:

5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
5-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
5-i-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

and

20 5-n-butyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

E) Similarly, proceeding as in Parts A and B above, but substituting the appropriate epoxide from Preparation 2 for 1-carbobenzyloxypiperidin-4-epoxide and methylamine, ethylamine, i-propylamine and n-butylamine for ammonia, the following compounds are prepared:

4,5-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
4-ethyl-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-

one;

30 one;
5-ethyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-

5-methyl-4-i-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; and

4-n-butyl-5-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

35

THIS PAGE BLANK (USPTO)

F) Similarly, proceeding as in Part A and B above, substituting α -chloropropionyl chloride, α -chlorobutryl chloride, and α -chlorohexanoyl chloride for α -chloroacetyl chloride, the following compounds are prepared:

2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
2-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; and
2-i-butyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

G) Similarly, proceeding as in Part A and B above, but substituting the appropriate amine for ammonia and the appropriate acid chloride for α -chloroacetyl chloride, the following compounds are prepared:

2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
from methylamine and α -chloropropionyl chloride;

2-ethyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
from methylamine and α -chlorobutryl chloride;

2-i-propyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
from methylamine and β -methyl- α -chlorobutayl chloride; and

2-n-butyl-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
from ethylamine and α -chlorohexanoyl chloride.

H) Similarly, proceeding as in Parts A and B above, but substituting the appropriate epoxide from Preparation 2 for 1-carbobenzyloxy-piperidin-4-epoxide α -chloropropionyl chloride, α -chlorobutryl chloride, and α -chlorohexanoyl chloride for α -chloroacetyl chloride, the following compounds are prepared:

2,5-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

2-ethyl-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

2-methyl-5-i-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; and

2-n-butyl-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

THIS PAGE BLANK (USPTO)

PREPARATION 4

To a mechanically stirred mixture of 31 g triphenylphosphine and 375 ml acetonitrile, 18.9 g
5 bromine is added dropwise over 20 minutes. The mixture is stirred 20 minutes at 0° and the ice bath is removed. A solution of 17 g of (2-hydroxyethyl)indole in 150 ml acetonitrile is added over 30 minutes. After stirring 2
10 hours at room temperature the mixture is diluted with 1000 ml diethyl ether. The liquid is decanted from the precipitated orange oil. The residue is washed with an additional 500 ml diethyl ether. The volume of the ethereal extracts is reduced to about 60 ml and the solution is filtered through 150 g silica gel with
15 diethyl ether. The solvent is removed to yield 3-(2-bromoethyl)indole, 22.5 g, white waxy solid, mp 57-60°.

Similarly, proceeding as above, substituting the appropriate hydroxyethylindole for 3-(2-hydroxy-
20 ethyl)indole, the following compounds are prepared:

3-(2-bromoethyl)-2-methylindole;
3-(2-bromoethyl)-1-methylindole;
3-(2-bromoethyl)-5-methoxyindole;
3-(2-bromoethyl)-5-n-butylindole; and
25 3-(2-bromoethyl)-6-methylindole..

EXAMPLE 1

(Preparation of compounds of formula (I))

30 A) A solution of the hydrobromide salt of 1-oxa-4,9-diazaspiro[5.5]undecan-3-one (15g) and 3-(2-bromoethyl)indole (13.5g) in 75 ml of dimethylformamide and 20 ml of triethylamine was stirred at 65°C for 16 hours. Water was added and the mixture was extracted with
35 methylene chloride. The organic layer was extracted with

THIS PAGE BLANK (USPTO)

5% hydrochloric acid and the aqueous layer was made basic with ammonium hydroxide and extracted with methylene chloride. Evaporation left a residue which was chromatographed on silica gel with 10% methanol-methylene chloride to give 8.0g of 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one as the free base, mp 48-50°C. The free base was dissolved in methanol and acidified with methanolic hydrochloric acid. The precipitate was washed with ether to give 7 g of the hydrochloride salt of 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one, mp 272-275°C (dec).

B) Similarly, proceeding as in Part A above, but substituting the appropriate substituted-1-oxa-4,9-diazaspiro[5.5]undecan-3-one from Preparation 3 for 1-oxa-4,9-diazaspiro[5.5]undecan-3-one, the following compounds are prepared:

- 9-[2-(3-indolyl)ethyl]-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 153-155°C;
- 9-[2-(3-indolyl)ethyl]-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 280-286°C;
- 9-[2-(3-indolyl)ethyl]-4-n-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 217-220°C;
- 9-[2-(3-indolyl)ethyl]-4-i-butyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 9-[2-(3-indolyl)ethyl]-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 175-177°C;
- 9-[2-(3-indolyl)ethyl]-5-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 240-243°C;
- 9-[2-(3-indolyl)ethyl]-5-i-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 9-[2-(3-indolyl)ethyl]-5-n-butyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

THIS PAGE BLANK (USPTO)

- 9-[2-(3-indolyl)ethyl]-4,5-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 210-212°C;
- 5 9-[2-(3-indolyl)ethyl]-4-ethyl-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 237-238°C;
- 9-[2-(3-indolyl)ethyl]-5-ethyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 266-268°C;
- 10 9-[2-(3-indolyl)ethyl]-5-methyl-4-i-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 9-[2-(3-indolyl)ethyl]-4-n-butyl-5-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 15 9-[2-(3-indolyl)ethyl]-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 260-263°C;
- 9-[2-(3-indolyl)ethyl]-2-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 236-239°C;
- 9-[2-(3-indolyl)ethyl]-2-i-butyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 20 9-[2-(3-indolyl)ethyl]-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt, m.p. 145-147°C;
- 9-[2-(3-indolyl)ethyl]-2-ethyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one, hydrochloride salt,
- 25 221-222°C;
- 9-[2-(3-indolyl)ethyl]-2-i-propyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 9-[2-(3-indolyl)ethyl]-2-n-butyl-4-ethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 30 9-[2-(3-indolyl)ethyl]-2,5-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 9-[2-(3-indolyl)ethyl]-2-ethyl-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
- 35 9-[2-(3-indolyl)ethyl]-2-methyl-5-i-propyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; and

THIS PAGE BLANK (USPTO)

9-[2-(3-indolyl)ethyl]-2-n-butyl-5-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

C) Similarly, proceeding as in Part A above, but substituting the appropriate bromoethylindole from Preparation 4 for 3-(2-bromoethyl)indole, the following compounds are prepared:

9-[2-(2-methylindol-3-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

9-[2-(1-methylindol-3-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

9-[2-(5-methoxyindol-3-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;

9-[2-(5-n-butylindol-3-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one; and

9-[2-(6-methylindol-3-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

EXAMPLE 2

8.0g of 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one was dissolved in methanol and acidified with methanolic hydrochloric acid. The precipitate was washed with ether to give 7.0g of the hydrochloride salt of 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one, m.p. 272-275°C (dec).

In similar manner, all compounds of formula (I) in base form can be converted to their pharmaceutically acceptable acid addition salts by treatment with the appropriate acid, for example, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methansulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and the like.

THIS PAGE BLANK (USE)

-24-

EXAMPLE 3

A solution of 3.5 g of 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one hydrochloride salt
5 in water (50 ml) was adjusted to pH 12 with ammonium hydroxide solution and extracted with methylene chloride. The methylene chloride was evaporated to afford 3 g of 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-
[5.5]undecan-3-one as the free base, mp 48-50°C.

10

EXAMPLE 4

The following example illustrates the preparation of representative pharmaceutical formulations containing an
15 active compound of Formula (I), e.g., 9-[2-(3-indolyl)-ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one.

I.V. Formulation

	Active compound	0.14 g
20	Propylene glycol	20 g
	Polyethylene glycol 400	20 g
	Tween 80	1 g
	0.9% Saline solution	100 ml

The active compound is dissolved in propylene
25 glycol, polyethylene glycol 400 and Tween 80. A sufficient quantity of 0.9% saline solution is then added with stirring to provide 100 ml of the I.V. solution which is filtered through a 0.2 micron membrane filter and packaged under sterile conditions.

30

	<u>TABLET FORMULATION</u>	<u>parts by weight</u>
	Active compound	50.0
	Magnesium stearate	0.75
	Starch	0.75
35	Lactose	29.0
	PVP (polyvinylpyrrolidone)	0.75

THIS PAGE BLANK (USPTO)

The above ingredients are combined and granulated using methanol as the solvent. The formulation is then dried and formed into tablets (containing 50 mg of active compound) with an appropriate tableting machine.

5

10

15

20

25


30

35

THIS PAGE BLANK (USPTO)

CLAIMS:

1. A compound of the formula



wherein:

- 15 R, R¹, R², R³, and R⁴ are independently hydrogen or lower alkyl of one to four carbon atoms; and R⁵ and R⁶ are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.

- 20 2. 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]-undecan-3-one and the pharmaceutically acceptable acid addition salts thereof.

- 25 3. A compound of claim 1 wherein R is lower alkyl of one to four carbon atoms and R¹, R², R³, R⁴, R⁵ and R⁶ are each hydrogen.

- 30 4. A compound of claim 3 selected from 5-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 5-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,5-diazaspiro-[5.5]-undecan-3-one, and 5-n-propyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,5-diazaspiro-[5.5]undecan-3-one; and the pharmaceutically acceptable acid addition salts thereof.

- 35 5. A compound of claim 1 wherein R, R¹ and R² are

THIS PAGE BLANK (USPTO)

independently hydrogen or lower alkyl of one to four carbon atoms and R^3 , R^4 , R^5 , and R^6 are hydrogen.

6. A compound of claim 5 selected from 4-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]-undecan-3-one, 4-ethyl-5-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4-methyl-5-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4-n-propyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4,5-dimethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 2-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 2-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]-undecan-3-one, 2,4-dimethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, and 2-ethyl-4-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one; and the pharmaceutically acceptable acid addition salts thereof.

20

7. A pharmaceutical composition comprising 10 to 90% by weight of a compound of claim 1 in admixture with 90 to 10% of a pharmaceutically acceptable, non-toxic carrier.


8. A compound of claim 1 for use in treating and/or preventing hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders and asthma in a mammalian subject.

9. A compound of claim 1 for use in treating and/or preventing hypertension in a mammalian subject.

10. A process for the preparation of a compound of claim 1, which comprises:

a) reacting a compound of the formula

THIS PAGE BLANK (USPTO)




5

wherein:

R^3 , R^4 , R^5 and R^6 are as defined in claim 1 and X is halo, or an acid addition salt thereof, with a compound represented by the formula

10



15

wherein:

R, R^1 , and R^2 are as defined in claim 1; or

b) converting a free base of Formula (I) of claim 1 to its acid addition salt, or


20

c) converting an acid addition salt to the corresponding free base of Formula (I) of claim 1.

THIS PAGE BLANK (USPTO)

CLAIMS:

1. A process for the preparation of the compound
of the formula




or the pharmaceutically acceptable acid addition salts
thereof, wherein:

15 R, R¹, R², R³ and R⁴ are independently hydrogen or
lower alkyl of one to four carbon atoms; and

R⁵ and R⁶ are independently hydrogen, lower alkyl of
one to four carbon atoms or lower alkoxy of one to four
20 carbon atoms, which comprises:


a) reacting a compound of the formula



wherein:

30 R³, R⁴, R⁵ and R⁶ are as defined above and X is
halo, or an acid addition salt thereof, with a compound
represented by the formula

THIS PAGE BLANK (CONT.)



5

wherein:

R, R¹, and R² are as defined above; or

b) converting a free base of Formula (I) to its
10 acid addition salt, or

c) converting an acid addition salt to the
corresponding free base of Formula (I).

15 2. A process according to claim 1 wherein 9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one or a pharmaceutically acceptable acid addition salt thereof is produced.

20 3. A process of claim 1 wherein R is lower alkyl of one to four carbon atoms and R¹, R², R³, R⁴, R⁵ and R⁶ are each hydrogen.

4. A process of claim 3 wherein 5-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one,
25 5-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]-undecan-3-one, and 5-n-propyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,5-diazaspiro-[5.5]undecan-3-one; or a pharmaceutically acceptable acid addition salt thereof is produced.


30

5. A process of claim 1 wherein R, R¹ and R² are independently hydrogen or lower alkyl of one to four carbon atoms and R³, R⁴, R⁵, and R⁶ are hydrogen.

THIS PAGE BLANK (USPTO)

6. A process of claim 5 wherein 4-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]-undecan-3-one, 4-ethyl-5-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4-methyl-5-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4-n-propyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 4,5-dimethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 2-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, 2-ethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]-undecan-3-one, 2,4-dimethyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one, or 2-ethyl-4-methyl-9-[2-(3-indolyl)ethyl]-1-oxa-4,9-diazaspiro-[5.5]undecan-3-one; or a pharmaceutically acceptable acid addition salt thereof is produced.

7. A process for producing a pharmaceutical composition comprising admixing 10 to 90% by weight of a compound of the formula




or a pharmaceutically acceptable acid addition salt thereof, wherein:

R, R¹, R², R³, and R⁴ are independently hydrogen, or lower alkyl of one to four carbon atoms;

R⁵ and R⁶ are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; with 90 to 10% of a pharmaceutically acceptable, non-toxic carrier.

THIS PAGE BLANK CONT

8. The use for treating and/or preventing hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders and asthma in a mammalian subject comprising administering to said subject of a compound of the formula



- or a pharmaceutically acceptable acid addition salt thereof, wherein:

- 15 R , R^1 , R^2 , R^3 , and R^4 are independently hydrogen or lower alkyl of one to four carbon atoms; and
- 20 R^5 and R^6 are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms or a pharmaceutical composition containing such compound as an active ingredient.

9. The use according to claim 8 for treating and/or preventing hypertension in a mammalian subject.

THIS PAGE BLANK (USPTO)



European Patent
Office

EUROPEAN SEARCH REPORT

0061333

Application number

EP 82 30 1460

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
D, Y	US-A-4 255 432 (SYNTEX) * abstract *	1,7	C 07 D 498/10 A 61 K 31/535 // (C 07 D 498/10 C 07 D 265/00 C 07 D 221/00)
Y	--- CHIMIE THERAPEUTIQUE, vol.VIII, no.4, July-August, 1973, Paris (FR), J. MAILLARD et al.: "Composes cycloalcanespiro heterocycliques. X.Synthese et etude pharmacologique de divers analogues structuraux de l'ethyl-4 oxo-2 (tetrahydro-1',2',3',4' naphtyl-2')8 oxa-1 diaza-3,8 spiro (4,5) decanone", pages 393-397 * page 394, compound 10; page 395, table II, compound 10 * -----	1,7	TECHNICAL FIELDS SEARCHED (Int. Cl. 3) C 07 D 498/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 03-06-1982	Examiner ALFARO I.
<div>CATEGORY OF CITED DOCUMENTS</div> <div>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</div> <div>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</div>			

THIS PAGE BLANK (USPTO)